Ilsung Pharm - Asset Resilience Ratio
Ilsung Pharm (003120) has an Asset Resilience Ratio of 26.21% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Ilsung Pharm's Asset Resilience Ratio has changed over time. Check Ilsung Pharm (003120) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Ilsung Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Ilsung Pharm.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩105.65 Billion | 26.21% |
| Total Liquid Assets | ₩105.65 Billion | 26.21% |
Asset Resilience Insights
- Very High Liquidity: Ilsung Pharm maintains exceptional liquid asset reserves at 26.21% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Ilsung Pharm Industry Peers by Asset Resilience Ratio
Compare Ilsung Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 15.57% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
Annual Asset Resilience Ratio for Ilsung Pharm (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Ilsung Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 26.21% | ₩105.65 Billion ≈ $71.60 Million |
₩403.01 Billion ≈ $273.11 Million |
-2.02pp |
| 2024-12-31 | 28.23% | ₩112.05 Billion ≈ $75.93 Million |
₩396.88 Billion ≈ $268.96 Million |
+10.26pp |
| 2023-12-31 | 17.97% | ₩75.33 Billion ≈ $51.05 Million |
₩419.19 Billion ≈ $284.08 Million |
+12.51pp |
| 2022-12-31 | 5.46% | ₩27.01 Billion ≈ $18.30 Million |
₩494.42 Billion ≈ $335.06 Million |
+1.90pp |
| 2021-12-31 | 3.57% | ₩13.24 Billion ≈ $8.97 Million |
₩371.38 Billion ≈ $251.68 Million |
+1.13pp |
| 2020-12-31 | 2.43% | ₩9.03 Billion ≈ $6.12 Million |
₩371.22 Billion ≈ $251.57 Million |
-1.54pp |
| 2019-12-31 | 3.98% | ₩14.69 Billion ≈ $9.95 Million |
₩369.52 Billion ≈ $250.42 Million |
-11.15pp |
| 2018-12-31 | 15.13% | ₩52.52 Billion ≈ $35.59 Million |
₩347.26 Billion ≈ $235.34 Million |
+11.89pp |
| 2017-12-31 | 3.24% | ₩11.25 Billion ≈ $7.62 Million |
₩347.46 Billion ≈ $235.47 Million |
-0.87pp |
| 2016-12-31 | 4.10% | ₩13.89 Billion ≈ $9.41 Million |
₩338.50 Billion ≈ $229.40 Million |
-13.18pp |
| 2015-12-31 | 17.28% | ₩63.43 Billion ≈ $42.99 Million |
₩367.03 Billion ≈ $248.73 Million |
-7.46pp |
| 2014-12-31 | 24.74% | ₩93.61 Billion ≈ $63.44 Million |
₩378.37 Billion ≈ $256.42 Million |
+1.20pp |
| 2013-12-31 | 23.54% | ₩87.73 Billion ≈ $59.45 Million |
₩372.66 Billion ≈ $252.55 Million |
-- |
About Ilsung Pharm
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, dige… Read more